Testing effectiveness (Phase 2)Study completedNCT04218266
What this trial is testing
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
Who this might be right for
Atrial Fibrillation (AF)
Bayer 755